Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist

Objective: To assess the effect of aromatase inhibitors with GnRH agonist for a severe symptomatic adenomyosis that is refractory to GnRH agonist and danazol with GnRH agonist. Design: Case report. Setting: Clinical practice in university hospital. Patient(s): A 34-year-old woman with a complaint of severe dysmenorrheal, symptomatic anemia, and a desire to retain fertility. Intervention(s): Aromatase inhibitor anastrozole given orally (1.0 mg or 2.0 mg daily) for 16 weeks and GnRH agonist given monthly (injected SC, 1.8 mg) for 4 months. Main Outcome Measure(s): Measurements of uterine volume and levels of serum E 2, estrone, A, dehydroepiandrosterone sulfate, LH, FSH, and CA125. Result(s): Uterine volume was reduced. The reduction rate of uterine volume estimated by magnetic resonance imaging and ultrasonography was 60% after 8 weeks of treatment. Conclusion(s): Aromatase inhibitor with GnRH agonist therapy was useful for the management of a severely adenomyotic woman whose desire was for conservative treatment. (Fertil Steril (R) 2007;87:1468.e9-12. (C) 2007 by American Society for Reproductive Medicine.)